Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. - Wikidata - wikimedia - TriplyDB

Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy.

Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy.

http://www.wikidata.org/entity/Q33597681

about

Reversing T cell immunosenescence: why, who, and how Innate and adaptive immune cells in the tumor microenvironment Treatment with IL-7 prevents the decline of circulating CD4+ T cells during the acute phase of SIV infection in rhesus macaques Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination Concepts of immunotherapy for glioma Mechanism of Action of IL-7 and Its Potential Applications and Limitations in Cancer Immunotherapy Engineered T cells for cancer treatment Interleukin-7 and Immunosenescence.The interaction of LCK and the CD4 co-receptor alters the dose response of T-cells to interleukin-7.IL-7 promotes CD95-induced apoptosis in B cells via the IFN-γ/STAT1 pathway.Redirecting the immune response: role of adoptive T cell therapy.IL-7 in human health and disease.Cdc25A-driven proliferation regulates CD62L levels and lymphocyte movement in response to interleukin-7.Immunotherapeutic effects of IL-7 during a chronic viral infection in mice.IL-7R expression and IL-7 signaling confer a distinct phenotype on developing human B-lineage cells.Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer.Single-Cell Characterization of in vitro Migration and Interaction Dynamics of T Cells Expanded with IL-2 and IL-7.Interferon-α inhibits CD4 T cell responses to interleukin-7 and interleukin-2 and selectively interferes with Akt signaling.Glut1-mediated glucose transport regulates HIV infection.Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes Therapeutic cancer vaccines: current status and moving forward.Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development Pulmonary delivery of interleukin-7 provides efficient and safe delivery to the aging immune system Effect of IL-7 Therapy on Naive and Memory T Cell Homeostasis in Aged Rhesus Macaques IL-7-Induced Glycerol Transport and TAG Synthesis Promotes Memory CD8+ T Cell Longevity.Common gamma chain cytokines in combinatorial immune strategies against cancer Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia.Multiple vaccinations: friend or foe.Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity.Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells.Dose response kinetics of CD8 lymphocytes from young animals transfused into old animals and challenged with influenza.Chemotherapy and immunotherapy: A close interplay to fight cancer?The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?Elevated systemic interleukin-7 in patients with colorectal cancer and individuals at high risk of cancer: association with lymph node involvement and tumor location in the right colon.The new normal: immunomodulatory agents against sepsis immune suppression.Sustained CD4(+) T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide.

P2860

Q27003902-11B6827A-E599-4CC4-9505-3789A5E80E25 Q27008342-5A0427BF-8965-42B4-A2BE-7FEC74FC6F62 Q27346577-279445E8-EC73-4BD3-BDB9-CAA272F11355 Q28068378-965EF211-12B5-4A75-B30E-565C0BEB9A29 Q28083888-12A3CB6A-5C52-4211-B7FE-CD4E114C4C64 Q28084138-8C583CC7-CEE2-491A-AAF2-78F4CC785E2C Q33578792-D5D6D209-1219-41D3-9AF0-8E91F50569C5 Q33582101-427FE7EE-38A7-421B-BA97-C8856A107629 Q33943574-67860CD8-A830-42A3-B6D8-ACA8955F08DF Q34110205-0DF79C23-EA2E-4699-BDA3-9CA66925A843 Q34123238-A72A4DA8-B945-4C56-9E7B-6E2C27559ADD Q34260682-B5E1E043-2273-4B4A-B338-FBBE45CBD56E Q34443792-6952DD8A-ECB0-4DA8-8F04-798A67479D96 Q35029432-785CF786-62E9-41C4-B44A-1CAE6BD40402 Q35182709-8A5794C2-AE6B-474C-BBEF-11145156C2F2 Q35223241-7D951393-9072-4D1D-A5A5-C9C37A59494C Q35318562-F99FE753-38C1-46E0-8B63-C1E5CCFD8C20 Q35545785-8566BAAB-FDD0-43DD-8B1E-74FB40292646 Q35627713-28DD063C-BCD0-4FA0-ABBF-CCB9E2A6C2A5 Q35787190-57449C7A-59BC-4F70-B548-0372A44E8503 Q35847903-32530C7C-DE37-4552-A902-B027433B5B2A Q35894347-FBD9FE5A-3C31-47E1-A0DC-CBE0194A0B48 Q36142490-DA941FA0-740D-4285-A9B0-611D148CE871 Q36162133-27D3F231-41F1-46AA-B6D0-5A6E777CCDF7 Q36166467-88145CDC-61FA-4FB6-9866-D034284D746A Q36197021-72914801-F0D7-460C-9ED3-CF3147714269 Q36439775-E196B155-8D53-4CC8-B2AD-0A7585CB9C6A Q36455872-20F82278-15CA-46AA-B7FE-DE8886A92A7F Q36462428-2BCDAFA6-9B74-4777-AC62-769D3DD1EF27 Q36622218-BFC41097-A764-42CB-B2F4-CFE6FC8DF4A7 Q36734688-08C5D865-55CB-4311-8D00-622F459C7B67 Q36835490-C468DD1F-5C05-4F3F-BE4F-CC9A03AB578A Q36940174-4E039D2A-E3D9-470C-866C-90ECB6AFCC84 Q37078985-6F7F7547-225B-4ADF-8BFC-C7F1A7B95ABE Q37151977-97BF3B34-6C1B-4568-BCAE-E375C6460E92 Q37222184-66C01565-63C9-4AA5-BD19-CE8EC962998D Q37563023-67BEBB74-1F90-45BC-9463-C5BBD960C793 Q37614711-B688FDAC-42B1-48D0-9D00-BC4604A7C029 Q37686624-078CCF9B-8EF8-4705-A171-492F810CF3A7 Q37732218-10A7491B-D922-4F8C-96DE-9AD3FC1592C3

P2860

Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy.

http://www.wikidata.org/entity/Q33597681

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase I study of recombinant h ...... ts with refractory malignancy.

@ast

Phase I study of recombinant h ...... ts with refractory malignancy.

@en

type

label

Phase I study of recombinant h ...... ts with refractory malignancy.

@ast

Phase I study of recombinant h ...... ts with refractory malignancy.

@en

prefLabel

Phase I study of recombinant h ...... ts with refractory malignancy.

@ast

Phase I study of recombinant h ...... ts with refractory malignancy.

@en

P1433

Q33597681-8226140B-A605-4880-BCDA-AE697F0162AC

P1476

Q33597681-673C221A-F279-4B4C-B6B4-21F4A27322FE

P2093

Q33597681-10C914F1-1A62-42DF-A7FD-E03D72B924D6

Q33597681-136DD2EE-B2E7-428A-B59C-822AD02B571C

Q33597681-1A163565-5E88-41B0-9992-9E73167B1B3A

Q33597681-251D518F-ABC0-4CDA-B9E9-4CB04022A0FF

Q33597681-28319CE2-B0B8-46E3-9DE5-BB69AF41CDB0

Q33597681-2C460327-3B4D-4CBA-8209-9187DF05A430

Q33597681-3BC94C3C-0BDA-4AD4-8E99-EB4E233A1623

Q33597681-3EEBB434-EC0B-4CC5-9956-66CCB7113B6E

Q33597681-4F0D211D-8172-4DAB-BC88-282E3E8C4C0B

Q33597681-567E5340-E68C-4539-8982-6C1D1C3346E7

P2860

Q33597681-04799C66-26B8-4F50-87FE-D833E6E750EC

Q33597681-0C20CB26-C843-460D-9D27-BF7EC73CCC0A

Q33597681-25FFB88D-D8A6-4C5E-8515-E068ED1E5701

Q33597681-3996E812-1EA9-4713-B52A-61107096340C

Q33597681-434F2128-A720-43B7-867B-4FECAFCAEE22

Q33597681-47D42A78-6F11-499A-920B-E58D68D2C79D

Q33597681-5D9DF3AC-A520-4FBD-A8AA-75AA0774BA58

Q33597681-62A8C7E5-6BED-4335-AE52-68299D3489B3

Q33597681-652BBB90-9944-4BAA-8AF5-0A1F8312E9CF

Q33597681-6543FE49-3FC9-4FAB-962D-2505A9F5B4B0

P304

Q33597681-18D179AC-BA5B-40A0-874C-C4F937504ED1

P31

Q33597681-6382ED6A-3618-46F1-914F-84FFA61C209C

P356

Q33597681-48FB801A-52ED-4B01-AF13-17F7E49F661C

P407

Q33597681-314B81C8-9146-42BA-93F5-025E51462AC6

P433

Q33597681-8A152DEC-AE9F-474B-AD53-27F52D54203C

P478

Q33597681-D059D8FB-6EEE-4810-9C7B-FBA92CB3AA47

P50

Q33597681-D301DE2D-1715-410F-8A73-25B34C6EB74A

P577

Q33597681-910F1837-1FDC-4965-A9DA-B447299D024D

P698

Q33597681-3C89A33A-3E50-416B-8642-FE5C4B4FE804

P921

Q33597681-099d8c71-9157-4980-b320-77b8d55097fe

P932

Q33597681-F4FD3C01-4AF8-4B0C-896B-690B6081B2FA

P356

1078-0432.CCR-09-1303

P1433

Clinical Cancer Research

P1476

Phase I study of recombinant h ...... ts with refractory malignancy.

@en

P2093

Andrew Pecora

http://www.w3.org/2001/XMLSchema#string

Catherine K Chow

http://www.w3.org/2001/XMLSchema#string

Claude Sportès

http://www.w3.org/2001/XMLSchema#string

Crystal L Mackall

http://www.w3.org/2001/XMLSchema#string

Frances T Hakim

http://www.w3.org/2001/XMLSchema#string

Irina Maric

http://www.w3.org/2001/XMLSchema#string

Julie Engel

http://www.w3.org/2001/XMLSchema#string

Margaret R Brown

http://www.w3.org/2001/XMLSchema#string

Maryalice Stetler-Stevenson

http://www.w3.org/2001/XMLSchema#string

Michel Morre

http://www.w3.org/2001/XMLSchema#string

P2860

IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells

Biological and clinical implications of interleukin-7 and lymphopoiesis

Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis

Interleukin-7: from bench to clinic

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

Interleukin-7 improves T-cell recovery after experimental T-cell-depleted bone marrow transplantation in T-cell-deficient mice by strong expansion of recent thymic emigrants.

Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys.

Interleukin-7: physiological roles and mechanisms of action.

Fates of human B-cell precursors.

Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo.

P304

727-735

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-1303

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Michael Krumlauf

P577

2010-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20068111

http://www.w3.org/2001/XMLSchema#string

P921

P932

2808195

http://www.w3.org/2001/XMLSchema#string